Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–5. https://doi.org/10.1126/science.aar4060.

Article  CAS  PubMed  PubMed Central  Google Scholar 

https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s096lbl.pdf. Accessed 27 Feb 2024.

Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Vandormael K, Riccio A, Yang J, Pietanza MC, Brahmer JR. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537–46. https://doi.org/10.1200/JCO.18.00149.

Article  CAS  PubMed  Google Scholar 

Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019;30(6):970–6. https://doi.org/10.1093/annonc/mdz127.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, Doi T, Moriwaki T, Kim SB, Lee SH, Bennouna J, Kato K, Shen L, Enzinger P, Qin SK, Ferreira P, Chen J, Girotto G, de la Fouchardiere C, Senellart H, Al-Rajabi R, Lordick F, Wang R, Suryawanshi S, Bhagia P, Kang SP, Metges JP, Investigators K-. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138–48. https://doi.org/10.1200/JCO.20.01888.

Article  CAS  PubMed  Google Scholar 

Tolaney SM, Barroso-Sousa R, Keenan T, Li T, Trippa L, Vaz-Luis I, Wulf G, Spring L, Sinclair NF, Andrews C, Pittenger J, Richardson ET 3rd, Dillon D, Lin NU, Overmoyer B, Partridge AH, Van Allen E, Mittendorf EA, Winer EP, Krop IE. Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor-positive, ERBB2-negative metastatic breast cancer: a randomized clinical trial. JAMA Oncol. 2020;6(10):1598–605. https://doi.org/10.1001/jamaoncol.2020.3524.

Article  PubMed  Google Scholar 

Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571–80. https://doi.org/10.1001/jamaoncol.2020.3370.

Article  PubMed  Google Scholar 

Matsumoto T, Fukuda K, Yoshida T, Shimazu K, Taguchi D, Shinozaki H, Seki K, Yamanaka T, Ootaka M, Nanjyo H, Watanabe H, Shibata H. Sudden and severe cardiotoxicity induced with pembrolizumab, its clinical course, therapeutic intervention, and outcome. Int Cancer Conf J. 2022;11(1):81–6. https://doi.org/10.1007/s13691-021-00525-8.

Article  PubMed  Google Scholar 

NdjanaLessomo FY, Wang Z, Mukuka C. Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: a meta-analysis. Front Oncol. 2023;13:1080998. https://doi.org/10.3389/fonc.2023.1080998.

Article  CAS  Google Scholar 

Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–8. https://doi.org/10.1001/jamaoncol.2018.3923.

Article  PubMed  PubMed Central  Google Scholar 

Sury K, Perazella MA, Shirali AC. Cardiorenal complications of immune checkpoint inhibitors. Nat Rev Nephrol. 2018;14(9):571–88. https://doi.org/10.1038/s41581-018-0035-1.

Article  CAS  PubMed  Google Scholar 

Fernandez Madrigal L, Montero Perez O, Rodriguez Garces MY, Inoriza Rueda A, Martinez Marcos FJ. Pericardial effusion with pembrolizumab. J Oncol Pharm Pract. 2022;28(7):1664–70. https://doi.org/10.1177/10781552221077974.

Article  CAS  PubMed  Google Scholar 

Sher AF, Golshani GM, Wu S. Fatal adverse events associated with pembrolizumab in cancer patients: a meta-analysis. Cancer Invest. 2020;38(2):130–8. https://doi.org/10.1080/07357907.2020.1721521.

Article  CAS  PubMed  Google Scholar 

Stein-Merlob AF, Rothberg MV, Holman P, Yang EH. Immunotherapy-associated cardiotoxicity of immune checkpoint inhibitors and chimeric antigen receptor T cell therapy: diagnostic and management challenges and strategies. Curr Cardiol Rep. 2021;23(3):11. https://doi.org/10.1007/s11886-021-01440-3.

Article  PubMed  PubMed Central  Google Scholar 

Pitts PJ, Louet HL, Moride Y, Conti RM. 21st century pharmacovigilance: efforts, roles, and responsibilities. Lancet Oncol. 2016;17(11):e486–92. https://doi.org/10.1016/S1470-2045(16)30312-6.

Article  PubMed  Google Scholar 

Baldo P, Fornasier G, Ciolfi L, Sartor I, Francescon S. Pharmacovigilance in oncology. Int J Clin Pharm. 2018;40(4):832–41. https://doi.org/10.1007/s11096-018-0706-9.

Article  PubMed  PubMed Central  Google Scholar 

Montane E, Santesmases J. Adverse drug reactions. Med Clin (Barc). 2020;154(5):178–84. https://doi.org/10.1016/j.medcli.2019.08.007.

Article  CAS  PubMed  Google Scholar 

https://www.pmda.go.jp/english/index.html, https://www.info.pmda.go.jp/fukusayoudb/CsvDownload.jsp. Accessed 22 Nov 2023.

www.pmrj.jp/jmo/php/indexj.php. Accessed 22 Nov 2023.

van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3–10. https://doi.org/10.1002/pds.668.

Article  CAS  PubMed  Google Scholar 

Ando G, Taguchi K, Enoki Y, Yokoyama Y, Kizu J, Matsumoto K. Evaluation of the expression time of ganciclovir-induced adverse events using JADER and FAERS. Biol Pharm Bull. 2019;42(11):1799–804. https://doi.org/10.1248/bpb.b19-00156.

Article  CAS  PubMed  Google Scholar 

Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius VR. Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 2013;36(10):995–1006. https://doi.org/10.1007/s40264-013-0061-7.

Article  PubMed  Google Scholar 

O’Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, Esteban E, Isla D, Martinez-Marti A, Faehling M, Tsuboi M, Lee JS, Nakagawa K, Yang J, Samkari A, Keller SM, Mauer M, Jha N, Stahel R, Besse B, Peters S, Investigators E-LEPK-. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23(10):1274–86. https://doi.org/10.1016/S1470-2045(22)00518-6.

Article  CAS  PubMed  Google Scholar 

Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, Bariani GM, De Jesus Acosta A, Doi T, Longo F, Miller WH, Oh DY, Gottfried M, Xu L, Jin F, Norwood K, Marabelle A. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33(9):929–38. https://doi.org/10.1016/j.annonc.2022.05.519.

Article  CAS  PubMed  Google Scholar 

Long GV, Robert C, Butler MO, Couture F, Carlino MS, O’Day S, Atkinson V, Cebon JS, Brown MP, Dalle S, Hill AG, Gibney GT, McCune S, Menzies AM, Niu C, Ibrahim N, Moreno BH, Diab A. Standard-dose pembrolizumab plus alternate-dose ipilimumab in advanced melanoma: KEYNOTE-029 cohort 1C, a phase 2 randomized study of two dosing schedules. Clin Cancer Res. 2021;27(19):5280–8. https://doi.org/10.1158/1078-0432.CCR-21-0793.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S, Investigators K-. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019;6(9):e459–69. https://doi.org/10.1016/S2352-3026(19)30110-3.

Article  PubMed  Google Scholar 

Cho J, Kim HS, Ku BM, Choi YL, Cristescu R, Han J, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. J Clin Oncol. 2019;37(24):2162–70. https://doi.org/10.1200/JCO.2017.77.3184.

Article  CAS  PubMed  Google Scholar 

Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, Manning M, Mogg R, Blumenschein WM, Tan MT, Subramaniam DS, Liu SV, Kaplan IM, McCutcheon JN. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2018;19(3):347–55. https://doi.org/10.1016/S1470-2045(18)30062-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Su L, Liu C, Wu W, Cui Y, Wu M, Chen H. Successful therapy for myocarditis concomitant with complete heart block after pembrolizumab treatment for head and neck squamous cell carcinoma: a case report with literature review. Front Cardiovasc Med. 2022;9:898756. https://doi.org/10.3389/fcvm.2022.898756.

Article  PubMed  PubMed Central  Google Scholar 

Cohen M, Mustafa S, Elkherpitawy I, Meleka M. A fatal case of pembrolizumab-induced myocarditis in non-small cell lung cancer. JACC Case Rep. 2020;2(3):426–30. https://doi.org/10.1016/j.jaccas.2019.12.045.

Article  PubMed  PubMed Central  Google Scholar 

Chen R, Peng L, Qiu Z, Wang Y, Wei F, Zhou M, Zhu F. Case report: cardiac toxicity associated with immune checkpoint inhibitors. Front Cardiovasc Med. 2021;8:727445. https://doi.org/10.3389/fcvm.2021.727445.

Article  PubMed  PubMed Central